deltatrials
Recruiting PHASE4 NCT06085183

Indigotindisulfonate Sodium as an Aid in Determination of Ureteral Patency in Patient's With Renal Impairment

An Open-Label, Randomized, Parallel Group Study to Investigate the Influence of Renal Impairment on the Efficacy and Safety of Two Doses of Bludigo™ When Used as an Aid in the Determination of Ureteral Patency

Sponsor: Prove pharm

Conditions Ureter Injury
Updated 6 times since 2023 Last updated: Jan 20, 2026 Started: Dec 20, 2023 Primary completion: Jun 30, 2026 Completion: Jul 31, 2026

A PHASE4 clinical study on Ureter Injury, this trial is actively recruiting participants. The trial is conducted by Prove pharm and has accumulated 6 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Nov 2023 – ~Feb 2024 · 3 months · monthly snapshotNot Yet Recruiting~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshotRecruiting~Mar 2025 – ~Feb 2026 · 11 months · monthly snapshotRecruiting~Feb 2026 – present · 48 days · monthly snapshot

Change History

6 versions recorded
  1. Feb 2026 — Present [monthly]

    Recruiting PHASE4

  2. Mar 2025 — Feb 2026 [monthly]

    Recruiting PHASE4

  3. Sep 2024 — Mar 2025 [monthly]

    Recruiting PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE4

  5. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE4

    Status: Not Yet RecruitingRecruiting

Show 1 earlier version
  1. Nov 2023 — Feb 2024 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Prove pharm
Data source: Prove pharm

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations